Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
AngioCloud
AngioCloud

AngioCloud

Angel

AngioCloud offers cloud-based medical imaging software for easy sharing and analysis of 3D vascular images, enhancing e-consults and surgical planning.

HQ
Atlanta, GA, US
Founded
2019
Overview
Compare
Fundraising
Employees

AngioCloud allows medical professionals to share and analyze 3D vascular images with unprecedented ease and flexibility. As a Cloud-based offering, the software allows any connected device (desktop or mobile) to share the kinds of high-quality images that were only available at a dedicated hospital workstation.

This ease of access will speed the planning of procedures requiring precise sizing, placement, and deployment of medical devices. E-consults, pre-surgical planning, and clinical decision support will greatly benefit from the advent of this technology.

AngioCloud - Similar Companies

VoxelCloud logo

VoxelCloud

MedClimate logo

MedClimate

eMedSoft logo

eMedSoft

AgileMD logo

AgileMD

agilemd.com

Gweepi Medical logo

Gweepi Medical

Frame Health logo

Frame Health

framehealth.com

Regard logo

Regard

withregard.com

AngioInsight logo

AngioInsight

angioinsight.com

ChoiceMap logo

ChoiceMap

Stasis Labs logo

Stasis Labs

stasislabs.com

BAND Connect logo

BAND Connect

bandconnect.net

Invio logo

Invio

CardioCube logo

CardioCube

LiteStack logo

LiteStack

Digital Medical Tech logo

Digital Medical Tech

AngioCloud - Quick Facts

Who are AngioCloud's competitors?

Companies similar to AngioCloud include VoxelCloud, MedClimate, eMedSoft and AgileMD.

When was AngioCloud founded?

AngioCloud was founded in 2019.

Where is AngioCloud's headquarters located?

AngioCloud's headquarters is located in Atlanta, GA, US.

When was AngioCloud's last funding round?

AngioCloud's most recent funding round was for $34.3k (USD) in March 2020.

How much has AngioCloud raised to-date?

As of Mar 2, 2020, AngioCloud has raised a total of $88.7k (USD).

How many employees does AngioCloud have?

AngioCloud has 50 employees as of Feb 4, 2024.

AngioCloud - Classification

Ownership
  • Private
  • Venture Capital
Technology
  • Cloud
Geographic Exposure
  • Global
Revenue
  • Recurring
Customer
  • Enterprise
Main Product
  • Medical Imaging
  • Software
Tags
  • Healthtech
  • SaaS
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 325000Chemical Manufacturing
  • 325410Pharmaceutical and Medicine Manufacturing
SIC
  • 5000Wholesale Trade-durable Goods
  • 5040Professional And Commercial Equipment And Supplies
  • 5047Medical, Dental, And Hospital Equipment And Supplies
Show 14 more industry codes
NAICS
  • 513200Software Publishers
  • 330000Manufacturing
  • 510000Information
  • 620000Health Care and Social Assistance
  • 513000Publishing Industries
  • 623000Nursing and Residential Care Facilities
  • 513210Software Publishers
SIC
  • 3900Miscellaneous Manufacturing Industries
  • 7300Business Services
  • 8000Health Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 8040Offices And Clinics Of Other Health Practitioners
  • 7372Prepackaged Software
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified